Literature DB >> 21707492

Targeting sphingosine-1-phosphate in hematologic malignancies.

Christina E Stevenson1, Kazuaki Takabe, Masayuki Nagahashi, Sheldon Milstien, Sarah Spiegel.   

Abstract

Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid mediator that regulates several processes important for hematologic cancer progression. S1P is generated by two sphingosine kinases, SphK1 and SphK2, and is exported outside the cell, where it activates specific cell surface S1P G-protein coupled receptors in autocrine/paracrine manner, coined "inside-out signaling". In this review, we highlight the importance of SphK1 and inside-out signaling by S1P in hematologic malignancy. We also summarize the results of studies targeting the SphK1/S1P/S1P receptor axis and the effects of the S1P receptor modulator, FTY720, in hematologic malignancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707492      PMCID: PMC3368248          DOI: 10.2174/187152011797655122

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  45 in total

1.  SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism.

Authors:  Michael Maceyka; Heidi Sankala; Nitai C Hait; Hervé Le Stunff; Hong Liu; Rachelle Toman; Claiborne Collier; Min Zhang; Leslie S Satin; Alfred H Merrill; Sheldon Milstien; Sarah Spiegel
Journal:  J Biol Chem       Date:  2005-08-23       Impact factor: 5.157

Review 2.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

3.  Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1.

Authors:  E Bonhoure; D Pchejetski; N Aouali; H Morjani; T Levade; T Kohama; O Cuvillier
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

4.  Runx regulation of sphingolipid metabolism and survival signaling.

Authors:  Anna Kilbey; Anne Terry; Alma Jenkins; Gillian Borland; Qifeng Zhang; Michael J O Wakelam; Ewan R Cameron; James C Neil
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

5.  Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.

Authors:  Vladimir Beljanski; Clayton S Lewis; Charles D Smith
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

6.  Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.

Authors:  Kathryn G Roberts; Amanda M Smith; Fiona McDougall; Helen Carpenter; Martin Horan; Paolo Neviani; Jason A Powell; Daniel Thomas; Mark A Guthridge; Danilo Perrotti; Alistair T R Sim; Leonie K Ashman; Nicole M Verrills
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

7.  Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression.

Authors:  Erwan Le Scolan; Dimitri Pchejetski; Yoshiko Banno; Nicole Denis; Patrick Mayeux; William Vainchenker; Thierry Levade; Françoise Moreau-Gachelin
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

8.  Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.

Authors:  James W Antoon; Martin D White; Evelyn M Slaughter; Jennifer L Driver; Hafez S Khalili; Steven Elliott; Charles D Smith; Matthew E Burow; Barbara S Beckman
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

9.  T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation.

Authors:  Hui Feng; David L Stachura; Richard M White; Alejandro Gutierrez; Lu Zhang; Takaomi Sanda; Cicely A Jette; Joseph R Testa; Donna S Neuberg; David M Langenau; Jeffery L Kutok; Leonard I Zon; David Traver; Mark D Fleming; John P Kanki; A Thomas Look
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

10.  STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors.

Authors:  Heehyoung Lee; Jiehui Deng; Maciej Kujawski; Chunmei Yang; Yong Liu; Andreas Herrmann; Marcin Kortylewski; David Horne; George Somlo; Stephen Forman; Richard Jove; Hua Yu
Journal:  Nat Med       Date:  2010-11-21       Impact factor: 53.440

View more
  12 in total

1.  Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells.

Authors:  Long Cheng; Yuan-Zheng Chen; Yi Peng; Nan Yi; Xin-Shi Gu; Yong Jin; Xu-Ming Bai
Journal:  Tumour Biol       Date:  2015-02-28

2.  Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.

Authors:  Giulia Marvaso; Agnese Barone; Nicola Amodio; Lavinia Raimondi; Valter Agosti; Emanuela Altomare; Valerio Scotti; Angela Lombardi; Roberto Bianco; Cataldo Bianco; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2014-03-21       Impact factor: 4.742

3.  Novel selective allosteric and bitopic ligands for the S1P(3) receptor.

Authors:  Euijung Jo; Barun Bhhatarai; Emanuela Repetto; Miguel Guerrero; Sean Riley; Steven J Brown; Yasushi Kohno; Edward Roberts; Stephan C Schürer; Hugh Rosen
Journal:  ACS Chem Biol       Date:  2012-09-14       Impact factor: 5.100

Review 4.  Sphingolipids and mitochondrial apoptosis.

Authors:  Gauri A Patwardhan; Levi J Beverly; Leah J Siskind
Journal:  J Bioenerg Biomembr       Date:  2016-04       Impact factor: 2.945

5.  Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.

Authors:  Francis R LeBlanc; Jennifer M Pearson; Su-Fern Tan; HeeJin Cheon; Jeffrey C Xing; Wendy Dunton; David J Feith; Thomas P Loughran
Journal:  Br J Haematol       Date:  2020-03-02       Impact factor: 6.998

Review 6.  Development of small-molecule inhibitors of sphingosine-1-phosphate signaling.

Authors:  Yvette Edmonds; Sheldon Milstien; Sarah Spiegel
Journal:  Pharmacol Ther       Date:  2011-08-27       Impact factor: 12.310

Review 7.  Influenza viral manipulation of sphingolipid metabolism and signaling to modulate host defense system.

Authors:  Madhuvanthi Vijayan; Bumsuk Hahm
Journal:  Scientifica (Cairo)       Date:  2014-01-23

8.  SphK2 over-expression promotes osteosarcoma cell growth.

Authors:  Dawei Xu; Hao Zhu; Chengniu Wang; Wei Zhao; Genxiang Liu; Guofeng Bao; Daoran Cui; Jianbo Fan; Fei Wang; Huricha Jin; Zhiming Cui
Journal:  Oncotarget       Date:  2017-11-06

9.  Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics.

Authors:  Cecilia Evangelisti; Camilla Evangelisti; Gabriella Teti; Francesca Chiarini; Mirella Falconi; Fraia Melchionda; Andrea Pession; Alice Bertaina; Franco Locatelli; James A McCubrey; Dong Jae Beak; Robert Bittman; Susan Pyne; Nigel J Pyne; Alberto M Martelli
Journal:  Oncotarget       Date:  2014-09-15

10.  Acid ceramidase is upregulated in AML and represents a novel therapeutic target.

Authors:  Su-Fern Tan; Xin Liu; Todd E Fox; Brian M Barth; Arati Sharma; Stephen D Turner; Andy Awwad; Alden Dewey; Kenichiro Doi; Barbara Spitzer; Mithun Vinod Shah; Samy A F Morad; Dhimant Desai; Shantu Amin; Junjia Zhu; Jason Liao; Jong Yun; Mark Kester; David F Claxton; Hong-Gang Wang; Myles C Cabot; Edward H Schuchman; Ross L Levine; David J Feith; Thomas P Loughran
Journal:  Oncotarget       Date:  2016-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.